Cardiff Oncology, Inc. Stock Analysis & AI Score
Cardiff Oncology, Inc. (CRDF) has an ST Score of 31.8 (C-), driven by its Forecast (B-) and held back by its Profitability (F). Analysts rate it Buy with a $2.00 price target (+56.3% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Cardiff Oncology, Inc. (CRDF) has an ST Score of 31.8 (C-), driven by its Forecast (B-) and held back by its Profitability (F). Analysts rate it Buy with a $2.00 price target (+56.3% upside).
- Strongest
- ForecastB-
- Weakest
- ProfitabilityF
All factor grades
- ForecastB-
- ValuationC
- Financial StrengthC
- MomentumC
- GrowthC-
- ProfitabilityF
- Piotroski2/9
Contact
CRDF stock: frequently asked questions
What is CRDF's ST Score?
Cardiff Oncology, Inc. (CRDF) has an ST Score of 31.8 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CRDF a buy, hold, or sell?
Analysts rate CRDF a Buy, with a price target of $2.00 (+56.3% vs the current price). Our ST Score grades it C- (31.8/100). The ST Score is a data-driven signal, not a recommendation.
What are CRDF's factor grades?
Valuation C, Profitability F, Financial Strength C, Momentum C, Growth C-, Forecast B-.
What is CRDF's valuation grade?
Cardiff Oncology, Inc. (CRDF) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CRDF's growth grade?
Cardiff Oncology, Inc. (CRDF) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CRDF's profitability grade?
Cardiff Oncology, Inc. (CRDF) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CRDF's financial strength grade?
Cardiff Oncology, Inc. (CRDF) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CRDF?
The average analyst price target for Cardiff Oncology, Inc. (CRDF) is $2.00 from 15 analysts, which is +56.3% versus the recent price of $1.28.
What is CRDF's Piotroski score?
Cardiff Oncology, Inc. (CRDF) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.